Seeking Alpha

Wedbush reiterates Buy rating on Prosensa

  • Wedbush is out reiterating a Buy rating on Prosensa (RNA).
  • "We anticipate potential top-line results from this trial could be presented in H2 2014," analyst Christopher Marai says, referring to news that RNA has dosed the first patient in a Phase 1/2 trial of PRO053.
  • "The market has broadly overlooked the opportunity for RNA's follow-on compounds," Marai adds, before predicting "approval worthy" Phase 3 data (presumably for drisapersen) in Q4 of this year.
  • "The big risk to the outcome of the Phase 3 study... is the effect that younger DMD boys (between 5 and 7) and those with greater walking ability at baseline will have on the overall results," Adam Feuerstein said Friday. "What we know now, but what GSK and RNA say they didn't know when the phase 3 study was started, is that DMD kids younger than 7 are generally still capable of improvements in six-minute walk distance without treatment."
  • Wedbush's price target is $50.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs